The latest fine is a record for a single company, imposed as what EU Competition Commissioner Neelie Kroes calls "a reasonable response to a series of quite unreasonable actions".
It provided drug developers seven years of market exclusivity for their inventions, ensuring that they would have a reasonable amount of time in which to make back their hefty investment, free of competition from other pharmaceutical firms.